Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tango Therapeutics, Inc.TNGX · Entity 1497 | General Counsel | February 04, 2025 | February 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tango Therapeutics, Inc.
Report date February 04, 2025 · Filed February 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,014 |
Ending reported balance
After 2025-02-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-04 · Sale · Disposed 2,774 · Balance 68,570 F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.86 to $3.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 2 · 2025-02-05 · Sale · Disposed 2,556 · Balance 66,014 F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $3.00 to $3.245 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.86 to $3.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $3.00 to $3.245 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2025 Filed Feb 7, 2025 01:21 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | SaleCommon Stock | 2,556 | $3.16 | $8,080.54 |
DisclosureSEC source: 0000950170-25-015704 · ownership.xml · nonDerivative · entry 2 Barry Douglas · CIK 0001890662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,014 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $3.00 to $3.245 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 04, 2025 Filed Feb 7, 2025 01:21 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | SaleCommon Stock | 2,774 | $2.99 | $8,288.71 |
DisclosureSEC source: 0000950170-25-015704 · ownership.xml · nonDerivative · entry 1 Barry Douglas · CIK 0001890662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,570 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.86 to $3.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 00:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 164,175 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0000950170-25-014808 · ownership.xml · derivative · entry 2 Barry Douglas · CIK 0001890662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,175 Underlying: Common Stock · 164,175 shares Expires 2035-02-03 F2 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 00:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 27,363 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-014808 · ownership.xml · nonDerivative · entry 1 Barry Douglas · CIK 0001890662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,344 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 2, 2026, 33% on February 1, 2027 and 34% on February 14, 2028, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 02:09 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | SaleCommon Stock | 1,354 | $12.62 | $17,087.21 |
DisclosureSEC source: 0000950170-24-012997 · ownership.xml · nonDerivative · entry 2 Barry Douglas · CIK 0001890662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,981 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $12.43 to $12.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 02:09 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | SaleCommon Stock | 1,422 | $12.56 | $17,864.02 |
DisclosureSEC source: 0000950170-24-012997 · ownership.xml · nonDerivative · entry 1 Barry Douglas · CIK 0001890662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,335 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $12.22 to $12.83 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:19 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 137,156 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0000950170-24-011248 · ownership.xml · derivative · entry 2 Barry Douglas · CIK 0001890662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,156 Underlying: Common Stock · 137,156 shares Expires 2034-02-01 F2 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2025, with the remaining option shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:19 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 22,859 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-011248 · ownership.xml · nonDerivative · entry 1 Barry Douglas · CIK 0001890662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,859 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 3, 2025, 1/3 on February 2, 2026 and 1/3 on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:06 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 143,391 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0000899243-23-006732 · doc4.xml · derivative · entry 2 Barry Douglas · CIK 0001890662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,391 Underlying: Common Stock · 143,391 shares Expires 2033-03-01 F2 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:06 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 23,898 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006732 · doc4.xml · nonDerivative · entry 1 Barry Douglas · CIK 0001890662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,898 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 5, 2024, 1/3 on February 3, 2025 and 1/3 on February 2, 2026 subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 69,500 | $0.00 Strike: $9.22 | $0.00 |
DisclosureSEC source: 0000899243-22-004605 · doc4.xml · derivative · entry 1 Barry Douglas · CIK 0001890662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,500 Underlying: Common Stock · 69,500 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2023, with the remaining option shares vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.